Search Result

Results for "

NS5A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug Metabolite (2) HCV (35) HCV Protease (11) Isotope-Labeled Compounds (3) SARS-CoV (5)
By Research Areas:	Cancer (3) Infection (41) Inflammation/Immunology (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-115981

NS5A-IN-2	HCV Protease	Infection
NS5A-IN-2 (Compound 33) is a potent inhibitor of *NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5*A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115982

NS5A-IN-3	HCV Protease	Infection
NS5A-IN-3 (Compound 15) is a potent inhibitor of *NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5*A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145375

NS5A-IN-1

HCV Protease Infection

NS5A-IN-1 is a proagent of the HCV NS5A inhibitor Pibrentasvir (ABT-530).

NS5A-IN-1	HCV Protease	Infection
NS5A-IN-1 is a proagent of the HCV NS5A inhibitor Pibrentasvir (ABT-530).

HY-146126

NS5A-IN-4	HCV Protease	Infection
NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with IC₅₀ values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against gT1b, gT1a, gT2a, gT3a, gT4a and *gT5a* . NS5A-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-111087

AZD-7295

HCV Protease Infection Inflammation/Immunology

AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

AZD-7295	HCV Protease	Infection Inflammation/Immunology
AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

HY-117411

Coblopasvir KW-136	HCV HCV Protease	Infection Inflammation/Immunology
Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A *(NS5A)* inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .

HY-117411A

Coblopasvir dihydrochloride KW-136 dihydrochloride	HCV HCV Protease	Infection
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A *(NS5A)* inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .

HY-147358A

Yimitasvir Emitasvir; DAG-181	HCV	Infection
Yimitasvir (Emitasvir) is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor. Yimitasvir can be used for research of chronic HCV infection .

HY-136267

HCV-IN-30

HCV Infection

HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

HCV-IN-30	HCV	Infection
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

HY-147358

Yimitasvir diphosphate Emitasvir diphosphate; DAG-181 diphosphate	HCV	Infection
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .

HY-147358C

(1R,4S)-Yimitasvir diphosphate (1R,4S)-Emitasvir diphosphate; (1R,4S)-DAG-181 diphosphate	HCV	Infection
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-16784

Samatasvir IDX719; IDX18719	HCV HCV Protease	Infection
Samatasvir (IDX71) is a potent, orally active *NS5A* inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC₅₀s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .

HY-124191

Ravidasvir hydrochloride PPI-668 hydrochloride	HCV	Infection
Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for hepatitis C virus (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC₅₀ of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .

HY-133018

HCV-IN-7	HCV	Infection
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .

HY-133018A

HCV-IN-7 hydrochloride	HCV	Cancer
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .

HY-101662

Pibrentasvir ABT-530	HCV	Infection
Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) *NS5A* inhibitor with EC₅₀s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

HY-10465

Daclatasvir dihydrochloride Maximum Cited Publications 44 Publications Verification BMS-790052 dihydrochloride; EBP 883 dihydrochloride	HCV	Infection
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active *HCV NS5A protein* inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-10466

Daclatasvir Maximum Cited Publications 44 Publications Verification BMS-790052; EBP 883	HCV	Infection
Daclatasvir (BMS-790052) is a potent and orally active *HCV NS5A protein* inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-145335

GSK2818713

HCV Protease Infection

GSK2818713 is a novel Hepatitis C NS5A replication complex inhibitor.
HY-133248

Daclatasvir Impurity C

Drug Metabolite Others

Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .
HY-133247

Daclatasvir Impurity B

Drug Metabolite Others

Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

GSK2818713	HCV Protease	Infection
GSK2818713 is a novel Hepatitis C *NS5A* replication complex inhibitor.

Daclatasvir Impurity C	Drug Metabolite	Others
Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

Daclatasvir Impurity B	Drug Metabolite	Others
Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-10465R

Daclatasvir dihydrochloride (Standard)	HCV	Infection
Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active *HCV NS5A protein* inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-N8188

Dehydrojuncusol	HCV HCV Protease	Infection
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35 µM) .

HY-133246

Monodes(N-carboxymethyl)valine Daclatasvir Daclatasvir Impurity A	HCV	Infection
Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-120713

MK-8325 dihydrochloride	HCV	Infection
MK-8325 (dihydrochloride) is an inhibitor of HCV NS5A with oral activity. MK-8325 exhibits minimal inhibition on hERG at the concentration of 30 mM .

HY-101663

Ruzasvir MK-8408	HCV	Infection
Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructural protein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC₉₀ ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model .

HY-15602B

Ledipasvir D-tartrate 25+ Cited Publications GS-5885 D-tartrate	HCV	Infection
Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15789

Elbasvir 5+ Cited Publications MK-8742	HCV	Infection
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-13997

Ombitasvir 5+ Cited Publications ABT-267	HCV	Infection
Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC₅₀s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

HY-15602A

Ledipasvir (acetone) 25+ Cited Publications GS-5885 acetone	HCV	Infection
Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602D

Ledipasvir (diacetone) GS-5885 diacetone	HCV	Infection
Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602

Ledipasvir 25+ Cited Publications GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-15789R

Elbasvir (Standard)	HCV	Infection
Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-12530

Velpatasvir 5+ Cited Publications GS-5816	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-15602AS

Ledipasvir-d6 hydrochloride GS-5885-d₆ hydrochloride	HCV Isotope-Labeled Compounds	Infection
Ledipasvir-d₆ hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-133246A

Monodes(N-carboxymethyl)valine Daclatasvir TFA Daclatasvir Impurity A TFA	HCV	Infection
Monodes(N-carboxymethyl)valine Daclatasvir TFA (Daclatasvir Impurity A TFA) is the TFA salt form of Monodes(N-carboxymethyl)valine Daclatasvir (HY-133246). Monodes(N-carboxymethyl)valine Daclatasvir TFA is the main degradation product of Daclatasvir (HY-10466). Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-15602S

Ledipasvir-d6 GS-5885-d₆	HCV SARS-CoV	Infection
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity .

HY-P0162

HCV-IN-4	HCV	Infection
HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC₉₀s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .

HY-12530R

Velpatasvir (Standard)	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-10466S

Daclatasvir-d6 BMS-790052-d₆; EBP 883-d₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

HY-10466S2

Daclatasvir-d16 BMS-790052-d₁₆; EBP 883-d₁₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

HY-125182

SMCypI C31	HCV	Infection
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .

Anti-Hepatitis C Virus Compound Library	288 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle. MCE offers a unique collection of 288 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8188

Dehydrojuncusol	Infection Structural Classification other families Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	HCV HCV Protease
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35 µM) .

Cat. No.	Product Name	Chemical Structure

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-15602AS

Ledipasvir-d6 hydrochloride
Ledipasvir-d₆ hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-10466S

Daclatasvir-d6
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

HY-10466S2

Daclatasvir-d16
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

NS5A

Inhibitors & Agonists

Screening Libraries

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products